GOTTLIEB, A.; BLAUVELT, A.; THA?I, D.; POULIN, Y.; BROCK, F.; ARENDT, C.; BOEHNLEIN, M.; REICH, K. Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 6, p. s84, 2020. DOI: 10.25251/skin.4.supp.84. Disponível em: https://jofskin.org/index.php/skin/article/view/1117. Acesso em: 22 jul. 2024.